What are Mission Vision & Core Values of Novo Nordisk Company?

The mission statement explicitly identifies the target customers: individuals suffering from diabetes, obesity, and rare blood and endocrine disorders. This focus shapes their product development and market strategies.

Novo Nordisk provides innovative treatments and solutions tailored to improve the lives of patients. This includes a wide range of pharmaceutical products and related services.

The company operates on a global scale, with its products marketed in approximately 170 countries. This widespread presence underscores its commitment to reaching patients worldwide.

The company's value lies in pioneering scientific breakthroughs, expanding access to medicines, and working towards prevention and cures. They aim to improve lives through innovation.

In 2024, Novo Nordisk invested approximately DKK 28.9 billion in Research and Development (R&D). This significant investment fuels their mission of scientific advancement.

Novo Nordisk aims to prevent more than 100 million people from developing type 2 diabetes by 2045. This ambitious goal highlights their dedication to long-term health solutions.

The Novo Nordisk Vision is distinctly future-oriented. It's about a world where chronic diseases are no longer a significant burden. This forward-thinking approach drives their innovation.

The company aims for a transformative impact on global health. This includes improving the lives of patients suffering from diabetes and other chronic diseases. Their goal is to create a healthier world.

Novo Nordisk seeks to disrupt the healthcare industry through continuous innovation. This involves pioneering new treatments, technologies, and approaches to disease management. This is a key part of their Novo Nordisk Strategy.

Novo Nordisk aspires to global market leadership in diabetes and other chronic diseases. They aim to be the leading provider of innovative solutions. This ambition is supported by their strong financial performance.

The vision is ambitious, yet grounded in reality. Novo Nordisk's financial performance, market dominance, and strategic investments suggest a realistic path to achieving its goals. They are well-positioned to realize their Novo Nordisk Goals.

Novo Nordisk's record-breaking revenue of DKK 290.4 billion in 2024, a 26% increase at constant exchange rates, largely driven by its GLP-1-based diabetes and obesity treatments like Ozempic and Wegovy, demonstrates its strong foundation for achieving its ambitious vision. Their success is a testament to their effective Marketing Strategy of Novo Nordisk.

Novo Nordisk's financial performance in 2024 vividly illustrates the success of its mission-driven strategy. The company reported a 26% sales growth at constant exchange rates, reaching DKK 290.4 billion, with operating profit also increasing by 26%. This growth was primarily driven by increased demand for GLP-1-based diabetes and obesity treatments.

The company's volume market share in the GLP-1 segment increased to 63% in 2024, and it served over 45.2 million people living with serious chronic diseases. This demonstrates the direct impact of the Novo Nordisk Mission on improving patient lives and expanding access to critical medications.

Lars Fruergaard Jørgensen, President and CEO, emphasized the direct link between the company's performance, strategic investments, and its commitment to its core purpose in February 2025. He highlighted the positive impact of serving over 45 million people and the progress in R&D, including obesity projects like CagriSema and amycretin.

The Novo Nordisk Mission and Novo Nordisk Vision shape day-to-day operations by guiding R&D priorities, manufacturing scale-up, and commercial execution. They also inform long-term planning, including expansion into new disease areas and global impact initiatives.

The commitment to the Novo Nordisk Mission and Novo Nordisk Vision is evident in the company's long-term strategic planning. This includes investments in R&D, manufacturing capacity, and market expansion, all geared towards improving patient outcomes and addressing unmet medical needs. This approach is also a key factor for Owners & Shareholders of Novo Nordisk.

The Core Values of Novo Nordisk are integral to the company's culture and decision-making processes, ensuring that all actions align with its mission and vision. These values guide ethical behavior, promote innovation, and foster a commitment to patients and stakeholders.

A primary example of Novo Nordisk's mission in action is its substantial investment in R&D. This directly supports its mission to 'pioneer scientific breakthroughs' and its vision to 'pioneer innovative solutions'.

In 2024, Novo Nordisk increased its R&D expenditures by a significant 48%, focusing on advancing its pipelines in obesity, diabetes, and cardiovascular diseases. This commitment led to successful clinical trials for new treatments, such as CagriSema, which demonstrated promising weight loss results. This focus on innovation is key to achieving its Novo Nordisk goals.

Another critical initiative is the expansion of manufacturing capacity to meet the rising global demand for its life-changing medicines. This directly aligns with Novo Nordisk's mission of 'expanding access to medicines' and its vision of improving the lives of more patients.

In 2024, Novo Nordisk invested over DKK 129 billion in scaling up its manufacturing capabilities, including the acquisition of three Catalent manufacturing sites. This strategic move ensures that over 45 million people currently benefiting from their treatments can continue to do so, and that future patients can access these innovations. This is a core component of the Novo Nordisk Strategy.

Leadership plays a critical role in reinforcing Novo Nordisk's mission, vision and core values throughout the organization. Lars Fruergaard Jørgensen, President and CEO, consistently communicates the company's purpose and strategic aspirations.

His statements, such as those made in February 2025 regarding the company's performance and continued focus on R&D and production capacity, serve to reinforce these principles internally and externally. The 'Novo Nordisk Way' framework further embeds these principles into the corporate culture, guiding employee behavior and decision-making. More about the company's origins can be found in the Brief History of Novo Nordisk.

The mission and vision are communicated to all stakeholders through various channels, including annual reports, investor presentations, and public statements. The Annual Report 2024, for instance, explicitly outlines the company's purpose and strategy, connecting financial performance with its societal contributions.

Concrete examples of alignment between stated values and actual business practices include patient-centricity, such as securing insurance coverage for Wegovy for approximately 55 million Americans with obesity. Furthermore, Novo Nordisk's commitment to sustainability is evident in its target to achieve zero CO2 emissions from operations and transport by 2045, and being the first pharmaceutical company to use 100% renewable power in all global production facilities. These initiatives demonstrate the core values of Novo Nordisk in action.